Intestinal failure-associated liver disease: Current challenges in screening, diagnosis, and parenteral nutrition considerations. [Review]
No Thumbnail Available
All Authors
Tabone, T.
Mooney, P.
Donnellan, C.
LTHT Author
Tabone, Trevor
Mooney, Peter
Donnellan, Clare
Mooney, Peter
Donnellan, Clare
LTHT Department
Gastroenterology
Non Medic
Publication Date
2024
Item Type
Journal Article
Review
Review
Language
Subject
Subject Headings
Abstract
Intestinal failure-associated liver disease (IFALD) is a serious life-limiting complication that can occur throughout the clinical course of intestinal failure and its management by parenteral nutrition (PN). Despite this, there is a lack of a standardized definition for IFALD, which makes this insidious condition increasingly difficult to screen and diagnose in clinical practice. Attenuating the progression of liver disease before the onset of liver failure is key to improving morbidity and mortality in these patients. This requires timely detection and promptly addressing reversible factors. Although there are various noninvasive tools available to the clinician to detect early fibrosis or cirrhosis in various chronic liver disease states, these have not been validated in the patient population with IFALD. Such tools include biochemical composite scoring systems for fibrosis, transient elastography, and dynamic liver function tests. This review article aims to highlight the existing real need for an accurate, reproducible method to detect IFALD in its early stages. In addition, we also explore the role PN plays in the pathogenesis of this complex multifactorial condition. Various aspects of PN administration have been implicated in the etiology of IFALD, including the composition of the lipid component, nutrient excess and deficiency, and infusion timing. We aim to highlight the clinical relevance of these PN-associated factors in the development of IFALD and how these can be managed to mitigate the progression of IFALD.
Journal
Nutrition in Clinical Practice